Market Reports

Global Drug Eluting Balloons (DEB) Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Published April 2010

Small vessel disease, bifurcated lesions, in-stent restenosis and peripheral vascular disease represent a nearly $2 billion market. In addition, the complications associated with long term antiplatelet therapy such as the risk of bleeding and contraindications limit the use of the current interventions. The associated cost and patient compliance for current treatments open the door for drug eluting balloons to these markets. More>>

Advances in the Use of Biomarkers in Biochip and Microarray Testing: Innovative technologies, growth opportunities and the future market outlook
Published Oct 2009

This report gives a strategic insight into the use of biomarkers in biochip and microarray testing. It offers an analysis of the current market landscape and forecast data for the industry going forward, and provides an overview of the key industry players and their areas of expertise. More>>

Cancer Personalized Medicine 2008
Published July 2008

The Cancer Personalized Medicine marketplace represents the paradigm for personalized medicine market evolution and Select Biosciences focuses in this report on the various commercialized cancer predictor tests, their current status, traction in the marketplace, quantitative market opportunities, and the factors that are driving as well as challenging the expansion of this space. Personalized Medicine, especially as it relates to Cancer, is undergoing significant growth and this report focuses i More>>

Cancer Stem Cells - Emerging Therapeutic, Diagnostic and Market Opportunities
Published

This report gives a comprehensive up-to-date review of global R&D on CSCs and strategies to target them. This includes around 30 companies or commercially based research organisations (including 20 SMEs and five major pharmaceutical companies) that are progressing drug discovery activities, including drug pipeline (pre-clinical to Phase III), discovery strategy, candidate molecules, drug targets, current clinical trials and related areas. More>>

Live-Licensing & In-life testing: R&D Processes and Regulation for New Drugs, 2008-2020
Published

Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as “in-life” testing or “live” licensing. Those proposals involve cumulative testing of the drug throughout its lifecycle. The industry would continually test drugs with smaller, more focused clinical trials. If a trial shows efficacy and safety, a live license would be given, allowing the company to market the drug in a limited manner. More>>

The Clinical Trials Market 2006
Published

The global clinical trials industry is currently worth an estimated $10 billion and has the potential for considerable growth in the future. Global revenues from clinical trials have increased by almost 15% in the last year and the industry is prepared for an extended period of healthy growth. Concern over safety and an extremely competitive pharmaceutical market has driven demand for large clinical trials but will also radically change how clinical trials are regulated and designed. More>>

MicroRNA 2008
Published February 2008

This report presents an exhaustive analysis of all the products and services offered by the various vendors into the microRNA market. Select Biosciences' proprietary market surveys addressed the qualitative and quantitative trends in the microRNA research market in terms of challenges, opportunities, and quantitative industry metrics—all the raw data and analyses based on the data are presented. In addition to the microRNA research market, this report also addresses the industry dynamics/trends More>>